Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
editorial
. 1994 Mar 26;308(6932):801–802. doi: 10.1136/bmj.308.6932.801

BCG vaccine in superficial bladder cancer.

N Sharma, S Prescott
PMCID: PMC2539986  PMID: 8167481

Full text

PDF
801

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Birch B. R., Harland S. J. The pT1 G3 bladder tumour. Br J Urol. 1989 Aug;64(2):109–116. doi: 10.1111/j.1464-410x.1989.tb05967.x. [DOI] [PubMed] [Google Scholar]
  2. Catalona W. J., Hudson M. A., Gillen D. P., Andriole G. L., Ratliff T. L. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol. 1987 Feb;137(2):220–224. doi: 10.1016/s0022-5347(17)43959-0. [DOI] [PubMed] [Google Scholar]
  3. Cookson M. S., Sarosdy M. F. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol. 1992 Sep;148(3):797–801. doi: 10.1016/s0022-5347(17)36724-1. [DOI] [PubMed] [Google Scholar]
  4. Heney N. M., Ahmed S., Flanagan M. J., Frable W., Corder M. P., Hafermann M. D., Hawkins I. R. Superficial bladder cancer: progression and recurrence. J Urol. 1983 Dec;130(6):1083–1086. doi: 10.1016/s0022-5347(17)51695-x. [DOI] [PubMed] [Google Scholar]
  5. Herr H. W., Laudone V. P., Badalament R. A., Oettgen H. F., Sogani P. C., Freedman B. D., Melamed M. R., Whitmore W. F., Jr Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol. 1988 Sep;6(9):1450–1455. doi: 10.1200/JCO.1988.6.9.1450. [DOI] [PubMed] [Google Scholar]
  6. Lamm D. L. Carcinoma in situ. Urol Clin North Am. 1992 Aug;19(3):499–508. [PubMed] [Google Scholar]
  7. Lamm D. L. Complications of bacillus Calmette-Guérin immunotherapy. Urol Clin North Am. 1992 Aug;19(3):565–572. [PubMed] [Google Scholar]
  8. Morales A., Eidinger D., Bruce A. W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976 Aug;116(2):180–183. doi: 10.1016/s0022-5347(17)58737-6. [DOI] [PubMed] [Google Scholar]
  9. Prescott S., James K., Hargreave T. B., Chisholm G. D., Smyth J. F. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol. 1992 Jun;147(6):1636–1642. doi: 10.1016/s0022-5347(17)37668-1. [DOI] [PubMed] [Google Scholar]
  10. Ratliff T. L., Gillen D., Catalona W. J. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol. 1987 Jan;137(1):155–158. doi: 10.1016/s0022-5347(17)43909-7. [DOI] [PubMed] [Google Scholar]
  11. Schellhammer P. F. BCG treatment of superficial transitional cell carcinoma. Urology. 1991;37(5 Suppl):16–18. doi: 10.1016/0090-4295(91)80130-y. [DOI] [PubMed] [Google Scholar]
  12. Soloway M. S., Perry A. Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C. J Urol. 1987 May;137(5):871–873. doi: 10.1016/s0022-5347(17)44277-7. [DOI] [PubMed] [Google Scholar]
  13. Utz D. C., Hanash K. A., Farrow G. M. The plight of the patient with carcinoma in situ of the bladder. J Urol. 1970 Feb;103(2):160–164. doi: 10.1016/s0022-5347(17)61913-x. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES